Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 2/20 | 0.76 |
| ▸ | NPC1 | O15118 | 1/20 | 0.76 |
| ▸ | RAF1 | P04049 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | FLT3 | P36888 | 8/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.64 |
| ▸ | CSF1R | P07333 | 2/20 | 0.63 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18676609 | 0.89 | ALDH1A1 (0.67) | KMT2AMEN1RAB9ANPC1RAF1 | |
| SCHEMBL19916663 | 0.88 | ALDH1A1 (0.65) | KMT2AMEN1RAB9ANPC1RAF1 | |
| SCHEMBL1012716 | 0.87 | RAB9A (0.76) | KMT2AMEN1RAB9ANPC1RAF1 | |
| SCHEMBL2518089 | 0.86 | MEN1 (1.00) | KMT2AMEN1RAB9ANPC1RAF1 | |
| SCHEMBL13234449 | 0.86 | KMT2A (0.74) | KMT2AMEN1RAB9ANPC1RAF1 | |
| SCHEMBL13234452 | 0.86 | MAPK14 (0.76) | KMT2AMEN1RAB9ANPC1RAF1 | |
| SCHEMBL13234446 | 0.86 | MAPK14 (0.74) | KMT2AMEN1RAB9ANPC1RAF1 | |
| SCHEMBL1010628 | 0.86 | KMT2A (0.74) | KMT2AMEN1RAB9ANPC1RAF1 | |
| SCHEMBL19916582 | 0.85 | RAB9A (0.54) | KMT2AMEN1RAB9ANPC1RAF1 | |
| SCHEMBL13234435 | 0.85 | MAPK14 (0.78) | KMT2AMEN1RAB9ANPC1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | KMT2A 334/4885MEN1 1454/4885RAB9A 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.